Search

Infectious disease

As a virus-infected model, the utilization of tonsil, adenoid, and lung organoids allows for the evaluation of antiviral drug efficacy and facilitates virus research.

0 +
Starting cost

Infectious disease

This model allows researchers to study the dynamics of viral entry, replication, and host response within the tonsil organoid system.
Lambda provides a comprehensive solution, offering the service of applying antiviral treatments such as Remdesivir.
This allows for an investigation into their therapeutic efficacy in reducing viral replication.

Cell Type

· ASC

Organoid type

· Tonsil organoid

This model allows researchers to study the dynamics of viral entry, replication, and host response within the adenoid organoid system.
Lambda provides a comprehensive solution, offering the service of applying antiviral treatments.
This allows for an investigation into their therapeutic efficacy in reducing viral replication.

Cell Type

· ASC

Organoid type

· Adenoid organoid

Lung organoids, mimicking the human lung, are instrumental in respiratory infection research.
Lambda specifically employs patient-derived lung organoids for assessing the effectiveness of antiviral drugs.
This approach enhances our understanding of disease pathogenesis, aids in drug discovery, contributes to vaccine development, and provides a physiologically relevant platform for studying host-pathogen interactions.

Cell Type

· ASC

Organoid type

· Lung organoid

Assay

Respiratory tract infection

Lung organoids, mimicking the human lung, are instrumental in respiratory infection research.
Lambda specifically employs patient-derived lung organoids for assessing the effectiveness of antiviral drugs.
This approach enhances our understanding of disease pathogenesis, aids in drug discovery, contributes to vaccine development,
and provides a physiologically relevant platform for studying host-pathogen interactions.

Assay process

Technical

Morphology analysis & qPCR

The lung organoids underwent treatment with an anti-viral drug, both before and after virus infection, with observations conducted at different drug concentrations.
As the drug concentration increased, there was a notable trend of decreasing virus titers, confirming the drug’s effectiveness in reducing the viral presence.